Antipsychotic Long-acting Injections

Antipsychotic Long-acting Injections (LAIs) were introduced in the 1960s to improve treatment adherence in schizophrenia. Subsequently, first-generation antipsychotic LAIs became widely used in many countries. Since the initial publication of Antipsychotic Long-acting Injections in 2010, new trial data have been published on long-acting injection (LAI) preparations of the drugs Risperidone, Paliperidone, and Olanzapine. Furthermore, a new LAI preparation of the drug Aripiprazole has recently been approved for clinical use in the United States and is likely to be approved in Europe soon. The second edition of this successful book has been fully updated to include this new data, with reference to both observational studies and randomized controlled trials, as well as other new developments in the clinical use of antipsychotic LAIs. New chapters have been added covering the comparison between oral and injectable antipsychotics, Olanzapine LAI, Aripiprazole LAI, and the practicalities of organizing a specialized clinic for long-acting injectable antipsychotics. Existing chapters have also been thoroughly updated to take into account the most recently published research. Antipsychotic Long-acting Injections, Second edition brings together clinical and research findings on LAIs in a comprehensive volume, with chapters written by international experts.

Dr Peter Haddad is Consultant Psychiatrist at Greater Manchester West Mental Health NHS Foundation Trust, UK and Honorary Clinical Professor of Psychiatry at the University of Manchester, UK. He has a major clinical and research interest in pharmacological treatment of major mental illnesses (depression, bipolar disorder, schizophrenia) including adherence. He is also interested in improving the physical health of those with serious mental illness.
Professor Tim Lambert is Professor of Psychiatry at Concord Clinical School at The University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney. In addition, he fulfils clinical duties for Sydney Local Health Network as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHiP). His current interests focus on services research (pharmacoepidemiology, developing novel relapse prevention, treatment resistance, and cardiometabolic services for the seriously mentally ill); the clinical pharmacology of LAI antipsychotics (first and second generation) and of the second-generation antipsychotics, particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially cardiometabolic syndromes; and incomplete recovery.
Professor John Lauriello is Professor and Chair of the Department of Psychiatry, University of Missouri, School of Medicine, Columbia, Missouri, USA. He specializes in the diagnosis and treatment of psychotic disorders, most notably schizophrenia.

- 1: Christoph U. Correll, Chris Abbott, Samuel J. Keith, and Peter Haddad: Antipsychotic treatment and adherence in schizophrenia - 2: Tim Lambert and David Taylor: Pharmacology of antipsychotic long-acting injections - 3: Peter Haddad and W. Wolfgang Fleischhacker: Adverse effects and antipsychotic long-acting injections - 4: Taishiro Kishimoto, Christoph U. Correll, and John M. Kane: Comparative effectiveness of oral antipsychotics and Long-acting Injectable Antipsychotics - 5: Mark Taylor and Polash Shajahan: First-generation antipsychotic long-acting injections - 6: Pierre Chue: Risperidone Long-acting Injection - 7: Muaid Ithman, Niels Beck, and John Lauriello: Paliperidone Long-Acting Injection - 8: Dieter Naber, Daniel Luedecke, and Daniel Schöttle: Olanzapine long-acting injection - 9: Ganesh Gopalakrishna, W. Wolfgang Fleischhacker, and John Lauriello: Aripiprazole Long Acting Injectable - 10: Robin Emsley, Bonga Chiliza, and Laila Asmal: Long-acting injectable antipsychotics in early psychosis - 11: Maxine X. Patel: Health professionals' and patients' attitudes to LAIs - 12: Mary Jane Tacchi, Jennifer Nendick, and Jan Scott: Patient choice and long-acting injectable medication - 13: Tim Lambert: Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective - 14: Tim Lambert: The management of a specialist clinic for long acting injectable antipsychotics - 15: Peter Haddad, Tim Lambert, and John Lauriello: The role of antipsychotic long-acting injections in clinical practice